SANDOSTATIN

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, Hong Kong SAR China, Ireland, Japan, Lithuania, Malta, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Turkey, UK.

Active ingredients

The drug SANDOSTATIN contains one active pharmaceutical ingredient (API):

1	Octreotide UNII 75R0U2568I - OCTREOTIDE ACETATE
	Octreotide is a synthetic octapeptide derivative of naturally occurring somatostatin with similar pharmacological effects, but with a considerably prolonged duration of action. It inhibits pathologically increased secretion of growth hormone (GH) and of peptides and serotonin produced within the GEP endocrine system.
	Read more about Octreotide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SANDOSTATIN Solution for injection	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
H01CB02	Octreotide	H Systemic hormonal preparations, excl. Sex hormones and insulins → H01 Pituitary and hypothalamic hormones and analogues → H01C Hypothalamic hormones → H01CB Somatostatin and analogues
Discover more medicines within H01CB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	6227R, 6228T, 6229W, 9508K, 9509L, 9510M
BR	Câmara de Regulação do Mercado de Medicamentos	526513701155411, 526513702151411, 526513703158418, 526514110079603, 526514110079703, 526514110079803, 526527204159311, 526527206151318
CA	Health Products and Food Branch	00839191, 00839205, 02049392, 02239323, 02239324, 02239325
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	17.775-2-09-03, 22.530-1-05-06, 348-MEE-0614
EE	Ravimiamet	1004926, 1875292, 1875304, 1875315, 1875326, 1875337, 1875348
ES	Centro de información online de medicamentos de la AEMPS	59559, 59561, 62139, 62140, 62141
FI	Lääkealan turvallisuus- ja kehittämiskeskus	057349, 057455, 379669, 379677, 379685, 442699
GB	Medicines & Healthcare Products Regulatory Agency	146702, 146710, 162403, 38124, 38776, 40676
HK	Department of Health Drug Office	32470, 32471, 33912, 44139, 44140, 44141
HR	Agencija za lijekove i medicinske proizvode	HR-H-463777391, HR-H-698681159
IE	Health Products Regulatory Authority	88175, 88176, 88177
JP	医薬品医療機器総合機構	2499403A1037, 2499403A2033
LT	Valstybinė vaistų kontrolės tarnyba	1007829
MT	Medicines Authority	MA1249/00601
NZ	Medicines and Medical Devices Safety Authority	5148, 5149, 5150, 5151, 5152, 5153
PL	Rejestru Produktów Leczniczych	100059987, 100059993, 100091258, 100091264, 100091270
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W59079001
SG	Health Sciences Authority	03808P, 03809P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699504750508
US	FDA, National Drug Code	0078-0180, 0078-0181, 0078-0182
ZA	Health Products Regulatory Authority	V/34/0232